AstraZeneca’s Voydeya Gets US FDA Approval As Add On To Ultomiris And Soliris

FDA approved the oral Factor D inhibitor for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemolgobinuria (PNH).

Plus sign
Voydeya is approved on top of Ultomiris or Soliris • Source: Shutterstock

More from Rare Diseases

More from Scrip